The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
December 23rd 2024
Exercise interventions may help manage chemotherapy-induced peripheral neuropathy (CIPN) in patients with ovarian cancer through improved physical activity and muscle function, but evidence remains limited.
What We’re Reading: Health Insurance Premiums; Drug Price Hikes; Postpartum Depression Pill Access
January 17th 2024Families with workplace health insurance may have missed out on $125,000 in earnings over the past 3 decades due to rising premiums; so far, there have been about 600 drug price hikes in January; experts worry that minority and low-income people will not have easy access to zuranolone, the first FDA-approved postpartum depression pill.
Read More
Real-Time CGM Shows Benefits Over Intermittently Scanned CGM in T1D
January 16th 2024In a systematic review and meta-analysis, real-time continuous glucose monitoring (CGM) demonstrated benefits in terms of time in range, hypoglycemia, and hyperglycemia among patients with type 1 diabetes (T1D).
Read More
Gabapentinoid Use in COPD Associated With Increased Severe Exacerbation Risk, Study Says
January 15th 2024Gabapentinoid use, namely gabapentin and pregabalin, was associated with increased risk for severe chronic obstructive pulmonary disease (COPD) exacerbation in patients with epilepsy, neuropathic pain, and other chronic pain.
Read More
High White Blood Cell Counts Are Associated With Long-Term Acute COPD Exacerbations, Study Says
January 13th 2024The study's findings suggest that high baseline white blood cell count, particularly high neutrophil count, was associated with a higher incidence of long-term acute exacerbation of chronic obstructive pulmonary disease (COPD).
Read More
Study Explores Treatment Discontinuation Rates, Resource Utilization Among Patients With CLL/SLL
January 12th 2024A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.
Read More
Health State Utility Scores for DMD-Related Impairment Need to Better Reflect Patient Input
January 12th 2024Patient-reported outcomes data regarding measures of health-related quality of life, also known as health state utilities, in Duchenne muscular dystrophy (DMD) are scarce, with current knowledge in this area concentrated in caregiver feedback.
Read More
Hypofractionated Chemoradiation Regimen With an Adaptive SABR Boost Shows Promise in NSCLC
January 12th 2024An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC).
Read More
Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy
January 12th 2024A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.
Watch